glp-1 shortage canada news today News: Latest Updates on Weight Loss and Diabetes Medications GLP-1 Drug Coverage in Canada

Published online January 14, 2026

In this comprehensive overview (see Methods and the search methodology in Supplementary Section 1), we aim to identify and describe pre-clinical, mechanistic and clinical studies on the effects of GLP-1RAs in cognitive and mental health disorders, and to provide a summary of available evidence and future perspectives

neuromuscular disorders that may cause muscle wasting, such as muscular dystrophy, spinal muscular atrophy or amyotrophic lateral sclerosis

In the ATTAIN-MAINTAIN trial, 205 patients taking tirzepatide and 171 patients taking semaglutide were randomized to take orforglipron or placebo (no active drug) daily for a year

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes

These vouchers followed agreements from Novo Nordisk and Lilly to cut prices on the drugs for Medicaid and Medicare patients